THALOMID (thalidomide)
ERYTHEMA NODOSUM LEPROSUM·+2
CELGENE
Indication
Prevention of cutaneous erythema nodosum leprosum lesion recurrence
Prevention of cutaneous erythema nodosum leprosum lesion recurrence is a maintenance indication aimed at suppressing repeated outbreaks of skin lesions in patients affected by erythema nodosum leprosum, also known as a type 2 lepra reaction. Read more about Prevention of cutaneous erythema nodosum leprosum lesion recurrence
2 drugs 2 manufacturers
Drugs that treat it
Common Prevention of cutaneous erythema nodosum leprosum lesion recurrence therapies.
THALOMID (thalidomide)
THALIDOMIDE AND DERIVATIVE IMMUNOMODULATORS·ERYTHEMA NODOSUM LEPROSUM·+2
CELGENE/BMS
Filter & compare in the drug finder →Opens the drug finder with Prevention of cutaneous erythema nodosum leprosum lesion recurrence preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of cutaneous erythema nodosum leprosum lesion recurrence is a maintenance indication aimed at suppressing repeated outbreaks of skin lesions in patients affected by erythema nodosum leprosum, also known as a type 2 lepra reaction.
This immune complex–mediated, systemic inflammatory complication primarily occurs in patients with multibacillary leprosy, specifically borderline lepromatous and lepromatous leprosy.
It is pathologically driven by a type III hypersensitivity reaction featuring immune complex deposition, intense neutrophilic infiltration, and heightened expression of inflammatory cytokines like tumor necrosis factor-alpha.
Clinically, recurrence manifests as episodic, debilitating crops of painful, erythematous subcutaneous nodules and plaques across the limbs, trunk, and face, often accompanied by systemic symptoms such as fever, arthralgia, and neuritis.
- nih.gov
Prevention of cutaneous erythema nodosum leprosum lesion recurrence is a maintenance indication aimed at suppressing repeated outbreaks of skin lesions in patients affected by erythema nodosum leprosum, also known as a type 2 lepra reaction This immune complex–mediated, systemic inflammatory complication primarily occurs in patients with multibacillary leprosy, specifically borderline lepromatous and lepromatous leprosy It is pathologically driven by a type III hypersensitivity reaction featurin...
- plos.org
Prevention of cutaneous erythema nodosum leprosum lesion recurrence is a maintenance indication aimed at suppressing repeated outbreaks of skin lesions in patients affected by erythema nodosum leprosum, also known as a type 2 lepra reaction This immune complex–mediated, systemic inflammatory complication primarily occurs in patients with multibacillary leprosy, specifically borderline lepromatous and lepromatous leprosy
- leprosy-information.org
This immune complex–mediated, systemic inflammatory complication primarily occurs in patients with multibacillary leprosy, specifically borderline lepromatous and lepromatous leprosy
- nih.gov
It is pathologically driven by a type III hypersensitivity reaction featuring immune complex deposition, intense neutrophilic infiltration, and heightened expression of inflammatory cytokines like tumor necrosis factor-alpha
- frontiersin.org
Clinically, recurrence manifests as episodic, debilitating crops of painful, erythematous subcutaneous nodules and plaques across the limbs, trunk, and face, often accompanied by systemic symptoms such as fever, arthralgia, and neuritis
Personalize your experience
Follow Prevention of cutaneous erythema nodosum leprosum lesion recurrence and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.